Novel cancer chemotherapy targeting mitochondrial mutations

In our recent study of a Swedish colorectal cancer (CRC) cohort of 1063 cases with near-complete 5-year survival data, we found acquired mutations in specific mtDNA genes that associated with overall survival rates.

The group of Associate Professor Yongsub Kim in Korea are pioneering innovative approaches for editing mitochondrial DNA, with significant potential for broad application.

Leveraging our existing collaboration between Korea and the Sjöblom group in Sweden, along with other co-applicants, we aim to:Investigate the impact of specific mtDNA mutations in CRC on mtDNA transcription and biological function, and their association with tumor initiation and progression, to enable therapeutic breakthroughs by targeting these alterations.To accomplish our main objective, we will focus on the following specific aims:1.

Identify recurring mtDNA mutations that may act as tumor inducers or tumor adaptive during CRC progression.2. Model and understand the biological consequences of mtDNA mutations in CRC.3.

Develop treatment strategies for CRC that target mtDNA mutations.The Swedish CRC cohort, the largest of its kind globally, provides an unparalleled platform to investigate specific genetic and demographic factors influencing disease onset and treatment response.

Utilizing state-of-the-art mtDNA editing technology to characterize mutations, we anticipate the development of groundbreaking therapeutic approaches for CRC, ultimately enhancing chemotherapeutic outcomes.